The Covid vaccine being studied by the University of Oxford and AstraZeneca would seem to give a strong immune response in the elderly.
The Financial Times writes it, anticipating the results of the phase 3 clinical trial in progress.
According to the newspaper, which cites 'two people with knowledge of the results', the vaccine stimulates the production of protective antibodies and T cells, a necessary but not sufficient condition to establish efficacy and which does not provide any information on safety. The immune response is similar to that already seen in adults between 18 and 55 years, already described in July. These results, too, reports the FT, will soon be published in a scientific journal. The Oxford vaccine, in the development of which the Italian company Irbm also participates, is one of those in the most advanced stage of development at the moment, with the first data on safety and efficacy expected within this year. The vaccine test in the US has just resumed, after a stop for the analysis of some side effects reported by the company.
